ANTICANCER RES 2020 10.21873/anticanres.14271
Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology
Park1, S; Cho, EY; Oh, YL; Park, YH; Kim, HS

ANN ONCOL 2020 10.1016/j.annonc.2020.01.072
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Schmid1, P; Salgado, R; Park, YH; Munoz-Couselo, E; Kim, SB; Sohn, J; Im, SA; Foukakis, T; Kuemmel, S; Dent, R; Yin, L; Wang, A; Tryfonidis, K; Karantza, V; Cortes, J; Loi, S

CANCERS 2020 10.3390/cancers12051306
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH

ANN ONCOL 2020 10.1016/j.annonc.2020.01.008
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Park1, YH; Senkus-Konefka, E; Im, SA; Pentheroudakis, G; Saji, S; Gupta, S; Iwata, H; Mastura, MY; Dent, R; Lu, YS; Yin, Y; Smruti, BK; Toyama, T; Malwinder, S; Lee, SC; Tseng, LM; Kim, JH; Kim, TY; Suh, KJ; Cardoso, F; Yoshino, T; Douillard, JY

SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z
Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
Kang1, D; Kim, IR; Park, YH; Im, YH; Zhao, D; Guallar, E; Ahn, JS; Cho, J

BREAST 2020 10.1016/j.breast.2019.10.007
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)
Kim1, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, HJ; Kim, YB; Chang, JS; Choi, DH; Park, YH; Kim, DY; Kim, TH; Choi, BO; Lee, SW; Kim, S; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Nam, JH; Yoon, WS; Kim, JH; Cha, J; Oh, YK; Kim, IA

NEW ENGL J MED 2020 10.1056/NEJMoa1910549
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid1, P; Cortes, J; Pusztai, L; McArthur, H; Kummel, S; Bergh, J; Denkert, C; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Foukakis, T; Fasching, PA; Cardoso, F; Untch, M; Jia, L; Karantza, V; Zhao, J; Aktan, G; Dent, R; O'Shaughnessy, J

NEW ENGL J MED 2020 10.1056/NEJMoa1914510
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Modi1, S; Saura, C; Yamashita, T; Park, YH; Kim, SB; Tamura, K; Andre, F; Iwata, H; Ito, Y; Tsurutani, J; Sohn, J; Denduluri, N; Perrin, C; Aogi, K; Tokunaga, E; Im, SA; Lee, KS; Hurvitz, SA; Cortes, J; Lee, CL; Chen, SQ; Zhang, L; Shahidi, J; Yver, A; Krop, I

J CLIN ONCOL 2020 10.1200/JCO.19.00368
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Schmid1, P; Abraham, J; Chan, S; Wheatley, D; Brunt, AM; Nemsadze, G; Baird, RD; Park, YH; Hall, PS; Perren, T; Stein, RC; Mangel, L; Ferrero, JM; Phillips, M; Conibear, J; Cortes, J; Foxley, A; de Bruin, EC; McEwen, R; Stetson, D; Dougherty, B; Sarker, SJ; Prendergast, A; McLaughlin-Callan, M; Burgess, M; Lawrence, C; Cartwright, H; Mousa, K; Turner, NC

BRIT J CANCER 2019 10.1038/s41416-019-0618-z
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sim1, SH; Park, IH; Jung, KH; Kim, SB; Ahn, JH; Lee, KH; Im, SA; Im, YH; Park, YH; Sohn, J; Kim, YJ; Lee, S; Kim, HJ; Chae, YS; Park, KH; Nam, BH; Lee, KS; Ro, J

LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA

BREAST CANCER RES TR 2019 10.1007/s10549-019-05400-y
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
Kim1, JY; Lee, E; Park, K; Im, SA; Sohn, J; Lee, KS; Chae, YS; Kim, JH; Kim, TY; Jung, KH; Park, YH

JAMA Oncol 2019 10.1001/jamaoncol.2019.0620
Insights Into Breast Cancer in the East vs the West: A Review
Yap1, YS; Lu, YS; Tamura, K; Lee, JE; Ko, EY; Park, YH; Cao, AY; Lin, CH; Toi, M; Wu, J; Lee, SC

BREAST CANCER RES TR 2019 10.1007/s10549-019-05318-5
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Yeo1, W; Ueno, T; Lin, CH; Liu, Q; Lee, KH; Leung, R; Naito, Y; Park, YH; Im, SA; Li, HP; Yap, YS; Lu, YS

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH

INT J CANCER 2019 10.1002/ijc.32188
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
Kim1, JY; Lee, E; Park, K; Jung, HH; Park, WY; Lee, KH; Sohn, J; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Im, SA; Park, YH

CANCER COMMUN 2019 10.1186/s40880-019-0375-7
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH

CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH

CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF

ONCOLOGIST 2019 10.1634/theoncologist.2018-0184
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J

BRIT J CANCER 2019 10.1038/s41416-019-0391-z
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Fujiwara1, Y; Mukai, H; Saeki, T; Ro, J; Lin, YC; Nagai, SE; Lee, KS; Watanabe, J; Ohtani, S; Kim, SB; Kuroi, K; Tsugawa, K; Tokuda, Y; Iwata, H; Park, YH; Yang, YS; Nambu, Y

SCI REP-UK 2019 10.1038/s41598-019-41098-0
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator
Oh1, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY

ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH

BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH

BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY

HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3
The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY

CANCER RES TREAT 2019 10.4143/crt.2017.562
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
Park1, IH; Im, SA; Jung, KH; Sohn, JH; Park, YH; Lee, KS; Sim, SH; Park, KH; Kim, JH; Nam, BH; Kim, HJ; Kim, TY; Lee, KH; Kim, SB; Ahn, JH; Lee, S; Ro, J

BREAST CANCER RES TR 2019 10.1007/s10549-018-5015-4
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea
Ryu1, JM; Choi, HJ; Kim, I; Nam, SJ; Kim, SW; Yu, J; Lee, SK; Choi, DH; Park, YH; Kim, JW; Seo, JS; Park, JH; Lee, JE; Kim, SW

INT J CANCER 2018 10.1002/ijc.31651
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA

J BREAST CANC 2018 10.4048/jbc.2018.21.e48
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY

EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH

CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S

BREAST CANCER RES TR 2018 10.1007/s10549-018-4863-2
Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy
Lee1, DY; Park, YH; Lee, JE; Choi, D

BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH

J BREAST CANC 2018 10.4048/jbc.2018.21.2.206
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
Cho1, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY

Oncoimmunology 2018 10.1080/2162402X.2018.1466768
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH

NAT COMMUN 2018 10.1038/s41467-018-04129-4
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH

J BREAST CANC 2018 10.4048/jbc.2018.21.1.91
Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy
Park1, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH

TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.002
Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast
Kim1, JY; Yu, JH; Nam, SJ; Kim, SW; Lee, SK; Park, WY; Noh, DY; Nam, DH; Park, YH; Han, W; Lee, JE

PHARMACOGENOMICS 2017 10.2217/pgs-2017-0044
The nuclear factor-kappa B pathway and response to treatment in breast cancer
Park1, YH

EUR J CANCER 2017 10.1016/j.ejca.2017.10.002
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH

NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

ONCOTARGET 2017 10.18632/oncotarget.21198
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
Kim1, JY; Park, D; Son, DS; Nam, SJ; Kim, SW; Jung, HH; Kim, YJ; Park, G; Park, WY; Lee, JE; Park, YH

BREAST 2017 10.1016/j.breast.2017.07.006
Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors
Heo1, MH; Cho, YJ; Kim, HK; Kim, JY; Park, YH

BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH

ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652
Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy
Kim1, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY

ONCOTARGET 2017 10.18632/oncotarget.17653
Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
Kim1, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH

Nat Commun. 2017 May 5;8:15081. doi: 10.1038/ncomms15081.
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung W11,2, Eum HH1,3, Lee HO1,4, Lee KM5,6, Lee HB5,7, Kim KT1, Ryu HS8, Kim S9, Lee JE9, Park YH10, Kan Z11, Han W5,7, Park WY1,2,4.

Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3.
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Park YH11, Kim TY2, Im YH1, Lee KS3, Park IH3, Sohn J4, Lee SH4, Im SA2, Kim JH5, Kim SH5, Lee SJ6, Koh SJ7, Lee KH8, Choi YJ9, Cho EK10, Lee S11, Kang SY12, Seo JH13, Kim SB14, Jung KH14.

Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.

Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
Park KH11, Lee S2, Park JH3, Kang SY4, Kim HY5, Park IH6, Park YH7, Im YH7, Lee HJ8, Park S9, Lee SI10, Jung KH11, Kim YS12, Seo JH13.

TRANSLATIONAL CANCER RESEARCH, FEB 2017, 6:S42-S43, DOI: 10.21037/tcr.2017.02.19
Defining the subset of the patients in whom "Less is More" for hormone receptor-positive breast cancer: clinical risk vs. genomics risk
1,Park YH

Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.
The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.

Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11.
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
Choi M11, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.

PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016.
Body Mass Index with Tumor F-18-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer
Hyun SH11, Ahn HK2, Lee JH1, Choi JY1, Kim BT1, Park YH3, Im YH3, Lee JE4, Nam SJ4, Lee KH1.

Cancer Res Treat. 2016 Oct;48(4):1373-1381. Epub 2016 Mar 23.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
Kim SH11, Jung KH2, Kim TY3, Im SA3, Choi IS4, Chae YS5, Baek SK6, Kang SY7, Park S8, Park IH9, Lee KS9, Choi YJ10, Lee S11, Sohn JH11, Park YH12, Im YH12, Ahn JH2, Kim SB2, Kim JH1.

Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.

Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.

Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.

PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016.
Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series
Lee MY11, Chang WJ1, Kim HS1, Lee JY1, Lim SH1, Lee JE2, Kim SW2, Nam SJ2, Ahn JS1, Im YH1, Park YH1.

SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804
The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH

Oncol Lett. 2016 Aug;12(2):1620-1622. Epub 2016 Jun 29.
Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients
Park JH11, Pahk K2, Kim S3, Lim SM4, Cheon GJ5, Park YH6, Lee SS7, Choe JG2.

Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.
Gene Expression Profiling of Breast Cancer Brain Metastasis
Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.

J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24.
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
Kim SW11, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.

Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11.
Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.

PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016.
The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
Lee JY11, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.

Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18.
Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.

Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5.
The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women
Kim J11, Han W2, Jung SY3, Park YH4, Moon HG5, Ahn SK6, Lee JW7, Kim MK5, Kim JJ5, Lee ES5, You TK1, Kang HS3, Lee ES3, Ro J3, Lee JE4, Nam SJ4, Yim YH4, Park IA5, Noh DY5.

BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9.
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
Lee SJ11, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.

Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.

Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13.
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
Lee JY11, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.

Oncotarget. 2015 Sep 15;6(27):24499-510.
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
Park K11, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.

Korean J Radiol. 2015 Sep-Oct;16(5):986-95. doi: 10.3348/kjr.2015.16.5.986. Epub 2015 Aug 21.
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
Ko ES11, Han H2, Han BK1, Kim SM3, Kim RB4, Lee GW5, Park YH6, Nam SJ7.

Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22.
Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study
Kang D11, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J.

Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
Park YH11, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG), Im YH.

J Breast Cancer. 2015 Jun;18(2):195-9. doi: 10.4048/jbc.2015.18.2.195. Epub 2015 Jun 26.
Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer
Kim Y11, Jung W1, Park YH2.

Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24.
Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea
Park YH11, Lee SJ1, Jung HA1, Kim SM1, Kim MJ1, Kil WH2, Lee JE2, Nam SJ2, Ahn JS1, Im YH3.

Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.
A seven-gene signature can predict distant recurrence in patients with triple- negative breast cancers who receive adjuvant chemotherapy following surgery
Park YH11, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.

Radiology. 2015 Apr;275(1):235-44. doi: 10.1148/radiol.14141129. Epub 2014 Dec 11.
Volume-based Metabolic Tumor Response to Neoadjuvant Chemotherapy Is Associated with an Increased Risk of Recurrence in Breast Cancer
Hyun SH11, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY.

J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27.
Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer
Yu JI11, Choi DH1, Huh SJ1, Park W1, Nam SJ2, Kim SW2, Lee JE2, Kil WH2, Im YH3, Ahn JS3, Park YH3.

Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology
Jung HA11, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.

J Breast Cancer. 2014 Dec;17(4):308-13. doi: 10.4048/jbc.2014.17.4.308. Epub 2014 Dec 26.
Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference
Han A11, Lee KE2, Lee HK3, Park YH4, Kim J5, Kim SW6, Jung KH7, Son BH8; Korean Breast Cancer Treatment Consensus Conference Panelists.

Asian Pac J Cancer Prev. 2014;15(20):8607-12.
Association between Socioeconomic Status and Altered Appearance Distress, Body Image, and Quality of Life Among Breast Cancer Patients
Chang O11, Choi EK, Kim IR, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Cho J.

Psychooncology. 2014 Oct;23(10):1103-10. doi: 10.1002/pon.3531. Epub 2014 Mar 24.
Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients
Choi EK11, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH, Cho J.

Cancer?Chemother Pharmacol.?2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
Choi MK11,?Park YH,?Kil WH,?Lee JE,?Nam SJ,?Ahn JS,?Im YH.

Oncology.?2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
Park YH11,?Im SA,?Cho EY,?Ahn JH,?Woo SY,?Kim S,?Keam B,?Lee JE,?Han W,?Nam SJ,?Park IA,?Noh DY,?Yang JH,?Ahn JS,?Im YH.

Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22.
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
Park LC11, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.

Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18.
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
Lee SY11, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.

Ann Oncol. 2014 Feb;25(2):346-51. doi: 10.1093/annonc/mdt476. Epub 2013 Dec 29.
Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients
Cho J11, Choi EK, Kim IR, Im YH, Park YH, Lee S, Lee JE, Yang JH, Nam SJ.

Br J?Cancer.?2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Park YH11,?Jung HA1,?Choi MK1,?Chang W1,?Choi YL2,?Do IG2,?Ahn JS1,?Im YH1.

Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16.
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
Park KH11, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.

Biochem Biophys Res Commun.?2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway
Park YH11,?Jung HH,?Ahn JS,?Im YH.

Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02

Cancer Res Treat. 2013 Mar;45(1):70-3. doi: 10.4143/crt.2013.45.1.70. Epub 2013 Mar 31.
A Case Report of Paraneoplastic Pemphigus Associated with Esophageal Squamous Cell Carcinoma
Cho JH11, Kim NJ, Ko SM, Kim C, Ahn HK, Yun J, Park YH.

Acta Oncol. 2013 Jan;52(1):73-81. doi: 10.3109/0284186X.2012.731520. Epub 2012 Oct 17.
Prognostic impact of FOXP3 expression in triple-negative breast cancer
Lee S11, Cho EY, Park YH, Ahn JS, Im YH.

Br J Cancer. 2012 Sep 25;107(7):1075-82. doi: 10.1038/bjc.2012.346. Epub 2012 Aug 23.
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
Yap YS11, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DW, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J.

Breast?Cancer Res Treat.?2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21.
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have be